B. Riley lowered the firm’s price target on Novavax to $12 from $15 and keeps a Buy rating on the shares post the Q3 report. The company’s new guidance framework with reduced reliance on near-term U.S. product sales is in line with expectations, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVAX: